[
  {
    "ts": "2026-02-23T09:09:00+00:00",
    "headline": "Merck RSV And KEYTRUDA Updates Refocus Attention On Valuation And Growth",
    "summary": "Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk infants during a second RSV season. The findings expand the potential use of ENFLONSIA beyond current approvals for RSV prevention in young children. The FDA also approved new formulations and indications for KEYTRUDA, including the first subcutaneous option and new uses for KEYTRUDA and KEYTRUDA QLEX in certain hard to treat cancers. For you as an investor, this news...",
    "url": "https://finance.yahoo.com/news/merck-rsv-keytruda-updates-refocus-090900730.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3c7651a1-95a3-332a-b998-5a03aae2a9eb",
      "content": {
        "id": "3c7651a1-95a3-332a-b998-5a03aae2a9eb",
        "contentType": "STORY",
        "title": "Merck RSV And KEYTRUDA Updates Refocus Attention On Valuation And Growth",
        "description": "",
        "summary": "Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk infants during a second RSV season. The findings expand the potential use of ENFLONSIA beyond current approvals for RSV prevention in young children. The FDA also approved new formulations and indications for KEYTRUDA, including the first subcutaneous option and new uses for KEYTRUDA and KEYTRUDA QLEX in certain hard to treat cancers. For you as an investor, this news...",
        "pubDate": "2026-02-23T09:09:00Z",
        "displayTime": "2026-02-23T09:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-rsv-keytruda-updates-refocus-090900730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-rsv-keytruda-updates-refocus-090900730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:00:00+00:00",
    "headline": "Merck Creates Separate Cancer Business as Sales Pressure Looms",
    "summary": "The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.",
    "url": "https://www.wsj.com/health/pharma/merck-creates-separate-cancer-business-as-sales-pressure-looms-2d6b1b65?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "1294a80f-f8cf-3e61-b2a8-5ff24999fc89",
      "content": {
        "id": "1294a80f-f8cf-3e61-b2a8-5ff24999fc89",
        "contentType": "STORY",
        "title": "Merck Creates Separate Cancer Business as Sales Pressure Looms",
        "description": "",
        "summary": "The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.",
        "pubDate": "2026-02-23T11:00:00Z",
        "displayTime": "2026-02-23T11:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1294a80f-f8cf-3e61-b2a8-5ff24999fc89/merck-creates-separate-cancer.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/22fcebf0a9c49f430c5039a9ef2297ad",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gj_W3CKizDFlEqCnTReZOw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/22fcebf0a9c49f430c5039a9ef2297ad.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/O_2Jg27ecAKYizf5qPXVDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/22fcebf0a9c49f430c5039a9ef2297ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/merck-creates-separate-cancer-business-as-sales-pressure-looms-2d6b1b65?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:45:00+00:00",
    "headline": "Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
    "summary": "RAHWAY, N.J., February 23, 2026--Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
    "url": "https://finance.yahoo.com/news/merck-evolves-human-health-operating-114500732.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "862311bc-1acf-3a08-932d-4f8a884908ec",
      "content": {
        "id": "862311bc-1acf-3a08-932d-4f8a884908ec",
        "contentType": "STORY",
        "title": "Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
        "description": "",
        "summary": "RAHWAY, N.J., February 23, 2026--Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
        "pubDate": "2026-02-23T11:45:00Z",
        "displayTime": "2026-02-23T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/d2635a4dae6648e9ac9e49a81f3e7d1a",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/brDlgYBCeDoZPtNGNwLAtg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d2635a4dae6648e9ac9e49a81f3e7d1a.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CQg0y8L1NoqejHlq3AwJFw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d2635a4dae6648e9ac9e49a81f3e7d1a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-evolves-human-health-operating-114500732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-evolves-human-health-operating-114500732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:40:29+00:00",
    "headline": "Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports",
    "summary": "Feb 23 () - Merck is splitting its human-health business into two ‚Äådivisions to offset pressures ‚Äårelated to the loss of patent for its ‚Äãtop-selling drug Keytruda, the Wall Street Journal reported on Monday. One division will house its cancer drugs, including ‚ÄåKeytruda, while ‚Å†the other will sell its non-cancer products, the report ‚Å†said.",
    "url": "https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "31473e69-3265-3725-b484-ff1ee5e5f35c",
      "content": {
        "id": "31473e69-3265-3725-b484-ff1ee5e5f35c",
        "contentType": "STORY",
        "title": "Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports",
        "description": "",
        "summary": "Feb 23 () - Merck is splitting its human-health business into two ‚Äådivisions to offset pressures ‚Äårelated to the loss of patent for its ‚Äãtop-selling drug Keytruda, the Wall Street Journal reported on Monday. One division will house its cancer drugs, including ‚ÄåKeytruda, while ‚Å†the other will sell its non-cancer products, the report ‚Å†said.",
        "pubDate": "2026-02-23T11:40:29Z",
        "displayTime": "2026-02-23T11:40:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/c184d10982098f00220e92d0693de11f",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OZli0WMw3h5V8hOA_ZD47A--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/c184d10982098f00220e92d0693de11f.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d6AJJeCNLAeEoligiOeiZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/c184d10982098f00220e92d0693de11f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:32:02+00:00",
    "headline": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
    "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
        "description": "",
        "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
        "pubDate": "2026-02-23T11:32:02Z",
        "displayTime": "2026-02-23T11:32:02Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "AAL"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "UAL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:41:07+00:00",
    "headline": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
    "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
        "description": "",
        "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
        "pubDate": "2026-02-23T14:41:07Z",
        "displayTime": "2026-02-23T14:41:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-novo.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "FBIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:46:08+00:00",
    "headline": "Stock Market Today: Dow Falls On New Trump Tariffs; Novo Plunges On Drug Trial Results (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index dropped Monday on higher Trump tariffs. Novo stock plunged on weight-loss drug trial results.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-trump-tariffs-novo-stock/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f65a060d-3459-3bd1-ba64-70ed322cb17d",
      "content": {
        "id": "f65a060d-3459-3bd1-ba64-70ed322cb17d",
        "contentType": "STORY",
        "title": "Stock Market Today: Dow Falls On New Trump Tariffs; Novo Plunges On Drug Trial Results (Live Coverage)",
        "description": "",
        "summary": "Stock Market Today: The Dow Jones index dropped Monday on higher Trump tariffs. Novo stock plunged on weight-loss drug trial results.",
        "pubDate": "2026-02-23T13:46:08Z",
        "displayTime": "2026-02-23T13:46:08Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f65a060d-3459-3bd1-ba64-70ed322cb17d/stock-market-today-dow-falls.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/95690600b5ffa388417bc5422e1bd05e",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NtJVppLb1ihUxFpSdY7qCg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/95690600b5ffa388417bc5422e1bd05e.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R3CWo1O2o1QmOITxDfYPLg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/95690600b5ffa388417bc5422e1bd05e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-trump-tariffs-novo-stock/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "QQQ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:23:00+00:00",
    "headline": "Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs",
    "summary": "Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a reorganisation that signals the US drugmaker is bracing for the biggest revenue hit in its recent...",
    "url": "https://www.proactiveinvestors.com/companies/news/1087774/merck-reportedly-ready-to-the-splits-as-keytruda-patent-cliff-looms-market-shrugs-1087774.html",
    "source": "Proactive",
    "provider": "yfinance",
    "raw": {
      "id": "8fa41e57-dca4-303d-b545-494dffda54cc",
      "content": {
        "id": "8fa41e57-dca4-303d-b545-494dffda54cc",
        "contentType": "STORY",
        "title": "Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs",
        "description": "",
        "summary": "Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a reorganisation that signals the US drugmaker is bracing for the biggest revenue hit in its recent...",
        "pubDate": "2026-02-23T13:23:00Z",
        "displayTime": "2026-02-23T13:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/proactive_us_504/45eb1789dd69a127a7dbf33b1f2fda45",
          "originalWidth": 1081,
          "originalHeight": 720,
          "caption": "Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CVbo_zRqLMr70OTvPTCqA--~B/aD03MjA7dz0xMDgxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/proactive_us_504/45eb1789dd69a127a7dbf33b1f2fda45.cf.webp",
              "width": 1081,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YTXowbK0vlde.LcQCRoL6g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/45eb1789dd69a127a7dbf33b1f2fda45.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Proactive",
          "url": "https://www.proactiveinvestors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.proactiveinvestors.com/companies/news/1087774/merck-reportedly-ready-to-the-splits-as-keytruda-patent-cliff-looms-market-shrugs-1087774.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-reportedly-ready-splits-keytruda-132300663.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:38:00+00:00",
    "headline": "Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.",
    "summary": "The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.",
    "url": "https://www.barrons.com/articles/merck-stock-keytruda-cancer-a764ae7e?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "a786f17b-faa9-34d8-9072-47e9eae09f9d",
      "content": {
        "id": "a786f17b-faa9-34d8-9072-47e9eae09f9d",
        "contentType": "STORY",
        "title": "Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.",
        "description": "",
        "summary": "The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.",
        "pubDate": "2026-02-23T12:38:00Z",
        "displayTime": "2026-02-23T12:38:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a786f17b-faa9-34d8-9072-47e9eae09f9d/merck-creates-separate-cancer.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/c0cbbf1f947d0dbaf24b2ce3e439e98c",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bgCqD0Y4ihIa0KYXy.mVUw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/c0cbbf1f947d0dbaf24b2ce3e439e98c.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OFOKhnn_Z6nYbidbEKSPeA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/c0cbbf1f947d0dbaf24b2ce3e439e98c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/merck-stock-keytruda-cancer-a764ae7e?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T08:38:28+00:00",
    "headline": "Merck to split cancer, specialty drug businesses in leadership shakeup",
    "summary": "Ahead of the looming loss of Keytruda‚Äôs exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.",
    "url": "https://www.biopharmadive.com/news/merck-cancer-specialty-split-business-pharmaceuticals/812805/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "d4f3a298-5d77-3e28-b27f-dbf964a0bda8",
      "content": {
        "id": "d4f3a298-5d77-3e28-b27f-dbf964a0bda8",
        "contentType": "STORY",
        "title": "Merck to split cancer, specialty drug businesses in leadership shakeup",
        "description": "",
        "summary": "Ahead of the looming loss of Keytruda‚Äôs exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.",
        "pubDate": "2026-02-23T08:38:28Z",
        "displayTime": "2026-02-23T08:38:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/f31ca00f9e76c858c91413db6a53edf1",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Merck & Co. logo displayed on the exterior of their research facility in San Francisco, Calif., on Sep. 21, 2020.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6U_SNeyRIvOLOp9wt6ta.g--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/f31ca00f9e76c858c91413db6a53edf1.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7fwz8LTIkTRsS0dXbCLcnQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/f31ca00f9e76c858c91413db6a53edf1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/merck-cancer-specialty-split-business-pharmaceuticals/812805/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-split-cancer-specialty-drug-083828244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:41:07+00:00",
    "headline": "Stocks to Watch Monday: Merck, Novo Nordisk, Eli Lilly, Gilead",
    "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Merck, Novo Nordisk, Eli Lilly, Gilead",
        "description": "",
        "summary": "üîé Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ‚ÜòÔ∏è Novo Nordisk (NVO), (DK:NOVO.",
        "pubDate": "2026-02-23T14:41:07Z",
        "displayTime": "2026-02-23T14:41:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "FBIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:45:00+00:00",
    "headline": "Merck Revamps Pharmaceutical Unit, Creating Separate Cancer Business",
    "summary": "The drugmaker is reorganizing to bolster product launches ahead its cancer drug Keytruda‚Äôs patent loss.",
    "url": "https://www.wsj.com/health/pharma/merck-creates-separate-cancer-business-as-sales-pressure-looms-2d6b1b65?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "1294a80f-f8cf-3e61-b2a8-5ff24999fc89",
      "content": {
        "id": "1294a80f-f8cf-3e61-b2a8-5ff24999fc89",
        "contentType": "STORY",
        "title": "Merck Revamps Pharmaceutical Unit, Creating Separate Cancer Business",
        "description": "",
        "summary": "The drugmaker is reorganizing to bolster product launches ahead its cancer drug Keytruda‚Äôs patent loss.",
        "pubDate": "2026-02-23T12:45:00Z",
        "displayTime": "2026-02-23T12:45:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1294a80f-f8cf-3e61-b2a8-5ff24999fc89/merck-revamps-pharmaceutical.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/22fcebf0a9c49f430c5039a9ef2297ad",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gj_W3CKizDFlEqCnTReZOw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/22fcebf0a9c49f430c5039a9ef2297ad.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/O_2Jg27ecAKYizf5qPXVDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/22fcebf0a9c49f430c5039a9ef2297ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/merck-creates-separate-cancer-business-as-sales-pressure-looms-2d6b1b65?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]